Dr Reddy's Laboratories is an API and finished-dose manufacturer based in India. It holds 279 active US drug master files and 90 valid CEPs. Its filings concentrate with US FDA, Health Canada and AIFA (IT). Its GMP standing is certified by ANVISA (Brazil), EMA and US FDA, among 10 authorities. Its most recent recorded inspection, by US FDA, closed on 14 November 2025 as NAI. Customs aggregates show $72.3M of exports covering 894 molecules to 64 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Hyderabad, United Arab Emirates | Not on file |
| Visakhapatnam, United Arab Emirates | Not on file |
| Visalhapatnam, United Arab Emirates | Not on file |
| São Paulo, Brazil | Not on file |
| SAO PAULO, Brazil | Not on file |
| Basel, Switzerland | Not on file |
34 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Atorvastatin | SFDA (Saudi Arabia), US FDA | 9 |
| Naproxen | EDQM, PMDA (Japan), US FDA | 8 |
| Omeprazole | EDQM, US FDA | 8 |
| Empagliflozin | SFDA (Saudi Arabia), US FDA | 7 |
| Rivaroxaban | EDQM, SFDA (Saudi Arabia), US FDA | 7 |
| Sitagliptin | EDQM, SFDA (Saudi Arabia), US FDA | 7 |
| Clopidogrel | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Esomeprazole | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Ondansetron | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Ciprofloxacin | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Montelukast | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Moxifloxacin | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Sumatriptan | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Ticagrelor | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Glimepiride | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Ketorolac | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Lenalidomide | SFDA (Saudi Arabia), US FDA | 4 |
| Levetiracetam | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Pantoprazole | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Pregabalin | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Rivastigmine | EDQM, US FDA | 4 |
| Valsartan | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Voriconazole | EDQM, US FDA | 4 |
| Amlodipine | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Atorvastatin Calcium | EDQM | 3 |
| Cabazitaxel | SFDA (Saudi Arabia), US FDA | 3 |
| Cabozantinib | US FDA | 3 |
| Capecitabine | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Cetirizine Dihydrochloride | EDQM, SFDA (Saudi Arabia) | 3 |
| Dapagliflozin | US FDA | 3 |
| Decitabine | SFDA (Saudi Arabia), US FDA | 3 |
| Desloratadine | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Dimethyl | SFDA (Saudi Arabia) | 3 |
| Docetaxel | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Dutasteride | SFDA (Saudi Arabia), US FDA | 3 |
| Enalapril | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Escitalopram | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Finasteride | EDQM, US FDA | 3 |
| Gemcitabine | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Icatibant | SFDA (Saudi Arabia), US FDA | 3 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | 691 | 10 |
| Health Canada | 409 | None |
| AIFA (IT) | 330 | None |
| ANVISA (Brazil) | 321 | 29 |
| MHRA (UK) | 185 | 4 |
| CDSCO (India) | 182 | 8 |
| EMA | None | 18 |
| MFDS (Korea) | None | 6 |
| INVIMA (CO) | None | 2 |
| TMDA (TZ) | None | 1 |
| EAEU_EEC | None | 1 |
| GOSPHARMNADZOR (BY) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $20.1M | 49 |
| 2025 | $3.8B | $72.3M | 64 |
| 2024 | $3.4B | Not reported | Not reported |
| 2023 | $3.0B | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Dr Reddy's Laboratories comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.